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ABSTRACT 
Breast cancer is one of the most common malignancies found in women and is associated with increased mortality in advanced disease. With the 
use of improved screening techniques and improvisation in treatment, 89% of the women diagnosed with breast cancer will survive 5 years from 
diagnosis. Despite significant advancement in the diagnosis and treatment of breast cancer, many patients succumb to this disease. The elucidation 
of aberrant signaling pathways that lead to breast cancer should help develop more effective therapeutic strategies. This review focuses on the 
different targets of breast cancer and how they can be acted upon by different animal venoms. 
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INTRODUCTION 
Female breast cancer is the most prevalent neoplasm worldwide 
with 5.2 million cases, and one in six cancer survivors in 2008 
diagnosed within the previous 5 years [1].  
Current treatment options include surgery, radiation and systemic 
therapy (e. g. Hormonal therapy, chemotherapy and biological 
therapy). Toxic side effects and emergence of drug resistance are the 
major problems faced with chemotherapy. The development of 
rational therapeutic approaches for breast cancer requires an 
understanding of the cellular signaling pathways leading to breast 
cancer. The development of successful therapeutic agents requires 
not only identification of appropriate molecular targets but, also 
elucidation of the signaling pathways that may contribute to the 
resistance to these agents. 
Targeting and characterizing the regulation of different pathways 
involved in anticancer can prove helpful in defining new therapeutic 
targets to develop chemotherapies with fewer side effects and 
toxicity, without compromising their therapeutic efficacy for 
treating cancer.  
The researchers have found a way, using the burgeoning field of 
nanotechnology, to pinpoint tumours for attack by melittin while 
largely shielding healthy cells. The resultant products, called 
nanobees, are injected into the blood stream, where they circulate 
until they reach and attack cancerous tumours. The approach also 
has the potential to avoid some of the toxic side effects seen in older 
cancer therapies like chemotherapy [2, 3]. 
It has been shown that the snake venom toxin inhibits growth of 
colon cancer cells through induction of apoptosis [4]. 
Snake venom toxin from Vipera lebetina turanica causes apoptotic 
cell death of ovarian cancer cells through the inhibition of NF-κB and 
STAT3 signal, which suggests that the snake venom toxin may be 
applicable as an anticancer agent for ovarian cancer [5]. A study 
used Cobra venom cytotoxin (CVC) loaded in poly (lactide-co-
glycolide) (PLGA) microspheres mixed with ricin and encapsulated 
in a thermosensitive PLGA-PEG-PLGA hydrogel.  
The in vivo experiments shows that intra tumoral injection of SSRP 
could inhibit hepatocellular carcinoma growth significantly, and the 
tumour growth inhibition rate reached 73.5% [6]. Crotoxin (CrTX), a 
potent neurotoxin extracted from the venom of the pit viper Crotalus 
durissus terrificus, produces significant anti-tumour effects on A549 
cell line by inducing cell apoptosis probably due to activation of 
P38MAPK and caspase-3, and by cell cycle arrest mediated by 
increased p53 expression. In addition, CrTX displays anti-angiogenic 
effects in vivo [7]. 
Cure for thousands of cases of cancer has emerged from the blue 
scorpion venom, endemic to Cuba. The blue scorpion venom 
contains a protein chain that attacks cancer. The "escozul" also acts 
as "immuno-modulator," raising the defences [8]. A treatment based 
on scorpion venom loaded with radioactive material is being tested 
as a way to kill brain tumour. A protein in venom from the yellow 
Israeli scorpion has been found to bind preferentially to the glioma 
cells, so scientists have created a synthetic version that does not by 
itself kill a patient. When the venom protein attaches to the glioma 
cells, the radiation kills them. Health physicists in a study used a 
compound called TM-601, a synthetic version of the molecule. The 
molecule, a protein, was bound to a radioactive substance called I-
131 believed to kill glioma cells [9]. 
Lewis tumour model has been established to explore the mechanism 
of polypeptide extract from scorpion venom (PESV) on promoting 
anti-tumour effects of cyclophosphamide (CTX). In this model, the 
extract was subcutaneously implanted into Lewis lung cells into 
C57BL/6 mice. Inhibition of expressions of VEGF and TGF-beta1, 
promotion of maturation of dendritic cells, recovery of antigen 
uptake presentation function, and reversal of immune injury to the 
body by CTX was seen with PESV, thus playing a role in inducing the 
tumour cell apoptosis [10]. 
Bufalin from the skin and parotid venom glands of toad has shown 
to induce apoptosis cell death in many types of cancer cell lines. It 
might be used as a therapeutic agent for the treatment of human 
bladder cancer [11]. Cinobufacini (Huachansu), an aqueous extract 
from the skins of Bufo bufo gargarizans Cantor, is a well-known 
traditional Chinese medicine widely used in 
clinical cancer therapy in China. These data suggested cinobufacini 
could induce apoptosis of hepatocellular carcinoma cells through 
mitochondria and FAS-mediated caspase-dependent pathways with 
an increase of treatment time, which might provide an experimental 
evidence for cinobufacini treatment in human hepatocellular 
carcinoma [12]. 
Evaluation of the anti-tumour potential of samsum ant venom (SAV) 
from Pachycondyla sennaarensis on the human breast carcinoma cell 
line MCF-7 has been done. It was found that SAV induces growth 
arrest of MCF-7 cells without affecting the viability of MCF-10 (non-
tumorigenic normal breast epithelial cells) and normal PBMCs [13]. 
This review provides a brief discussion on selected targets for breast 
cancer. 
Bee Venom 
Bee venom contains several physiologically active components. Two 
of the most toxic compounds are melittin and phospholipase A2 
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(PLA2). Melittin constitutes 30% to 50% of dry bee venom, and 
PLA2 makes up about 10% to 12% of bee venom. Melittin is a potent 
hemolytic that causes mast cell degranulation and activates PLA2. 
Other constituents in bee venom include hyaluronidase, apamin, 
mast cell degranulating peptide (MCD peptide), procamine, secapin, 
tertiapin, and other small peptides including adolapin along with 
histamine, dopamine, and noradrenaline. In desensitization to bee 
stings, hymenoptera venom stimulates an allergenic response, 
decreases leukocyte sensitivity to the allergen, and increases the 
number of T-suppressor cells [14].  
Bee venom (BV) (also called as apitoxin) has been widely used in 
the treatment of some immune-related diseases, as well as in recent 
times, in the treatment of tumours. Several cancer cells, including 
renal, lung, liver, prostate, bladder, and mammary cancer cells as 
well as leukaemia cells, can be the targets of bee venom peptides 
such as melittin and PLA2. Cell cytotoxic effects through the 
activation of PLA2 by melittin have been suggested to be the critical 
mechanism for the anti-cancer activity of BV [15]. 
Bee venom is a complex mixture of proteins, peptides and low 
molecular components. BV has numerous polypeptides, the main 
one being melittin, which shows anticancer effect. 
Potential targets of BV 
Cyclooxygenase 2 (COX-2) 
The main target of non-steroidal anti-inflammatory drugs (NSAID) 
action is COX. COX-2 has been implicated in mammary 
carcinogenesis in several ways. The COX-2 expression has been 
localized to the epithelial compartment with no expression within 
the stromal component. Studies of breast cancer cell lines have 
provided data supporting the over expression of COX-2 in breast 
cancer. A study of the differential expression of COX-1 and COX-2 in 
human breast cancer cell lines found that in the MCF7 estrogen 
receptor-positive cell line, COX-2 was barely detectable, whereas in 
the highly invasive, metastatic cell line MDA-MB- 231 there was a 
low level of COX-1 but a high level of COX-2 expression [16].  
It has been shown that melittin and bee venom prevent 
lipopolysaccharide and sodium nitroprusside-induced nitric oxide 
and prostaglandin E2 production via JNK pathway dependent 
inactivation of NF-κB, and suggests that inactivation of JNK 
pathways may also contribute to the anti-cancer effects of melittin 
and bee venom [17]. 
Also, the anti-inflammatory activity of the n-hexane, ethyl acetate, 
and aqueous partitions from BV (Apis mellifera) has been studied 
using COX activity and pro-inflammatory cytokines (TNF-alpha and 
IL-1beta) production, in vitro. The aqueous partition of BV showed 
strong dose-dependent inhibitory effects on COX-2 activity (IC50 = 
13.1 µg/mL). The aqueous partition was subfractionated into three 
parts by molecular weight differences, namely, B-F1 (above 20 KDa), 
B-F2 (between 10 KDa and 20 KDa) and B-F3 (below 10 KDa). B-F2 
and B-F3 strongly inhibited COX-2 activity and COX-2 mRNA 
expression in a dose-dependent manner, without revealing cytotoxic 
effects. TNF-alpha and IL-1beta, are potent pro-inflammatory 
cytokines and are early indicators of the inflammatory process. The 
effects of three subfractions on TNF-alpha and IL-1beta production 
were investigated using ELISA method. All three subfractions, B-F1, 
B-F2 and B-F3, inhibited TNF-alpha and IL-1beta production. These 
results suggest that the pharmacological activities of bee venom on 
anti-inflammatory process include the inhibition of COX-2 
expression and the blocking of pro-inflammatory cytokines (TNF-
alpha, and IL-1beta) production [18]. 
Aromatase 
Breast and endometrial cancers are highly responsive to oestrogen 
for growth evident by high concentrations of oestrogen receptors in 
these tissues. Malignant breast and endometrial tumours also 
produce large amounts of oestrogen locally via over expressing 
aromatase compared to their normal counterparts. In particular, 
aromatase over expression in breast cancer tissue has shown to be 
critical, since the use of aromatase inhibitors is clearly therapeutic in 
breast cancer [19]. 
Aromatase inhibitors (AIs) and inactivators interfere with the body’s 
ability to produce oestrogen from androgens by suppressing 
aromatase enzyme activity. Three generations of AIs have been 
developed. Each successive generation has been associated with 
higher specificity for the aromatase enzyme, fewer adverse events, 
and greater suppression of aromatase activity [20]. 
Letrozole is a highly potent and selective AI that inhibits the enzyme 
activity of intracellular aromatase at the major sites where it is 
found, resulting in almost complete suppression of whole body 
aromatization. By effectively blocking oestrogen synthesis, letrozole 
inhibits the growth or induces the regression of hormone-
responsive breast tumours in vivo. Letrozole induces complete 
regression of oestrogen-dependent, 9, 10-dimethylbenz-a-
anthracene (DMBA)-induced mammary tumours in adult female 
rats. The chemical structure of letrozole (4, 40-[(1H-1, 2, 4-triazol-1-
yl) methylene] bis-benzonitrile) is compared with other AIs. The 
nitrogen-containing structures like the imidazoles and the triazoles 
bind to the iron in the heme moiety of CYP-450, whereas the 
cyanobenzyl moiety present in the nonsteroidal AIs, such as 
letrozole, partially mimics the steroid backbone of the enzyme’s 
natural substrate, androstenedione [21]. 
Melittin, present in BV which has a powerful haemolytic activity, 
[22] is a known activator of phospholipase A₂, suppresses the 
aromatase activity of physically dissociated trophoblast cells in a 
dose-dependent manner and acts as an aromatase inhibitor. 
Interestingly, melittin suppressed aromatase activity during short 
term (3 h) incubation but was ineffective on trophoblast cells from 
24 h and 48 h incubations [23]. 
Free Radicals 
Free radicals are ubiquitous in our body and are generated by 
normal physiological processes, including aerobic metabolism and 
inflammatory responses, to eliminate invading pathogenic 
microorganism. Targets of free radicals in inflammation include 
DNA, proteins, RNA and lipids. As free radicals can inflict cellular 
damage, several defences have evolved, both to protect our cells 
from radicals and to repair DNA damage [17]. 
The radical theory in human physiology claims that the active free 
radicals are involved in almost all the cellular degradation process 
and leads to cell death. An antioxidant is a molecule capable of 
slowing or preventing the oxidation of other molecules and so to 
prevent such changes. Oxidative stress is thought to contribute to 
the development of chronic and degenerative diseases such as 
cancer, autoimmune disorders, aging, cataract, rheumatoid arthritis, 
cardiovascular and neurodegenerative diseases [24]. Propolis, 
pollen and honey have the highest antioxidant activities [25]. 
Bee venom is a potent antioxidant, antifungal, antibacterial, anti-
inflammatory, and possesses radioprotectant actions. It has been 
found to exert powerful actions as an antibacterial agent, anti-
inflammatory, antiarthritic, antirheumatic, in neurodegenerative 
disease, as a cardiotonic, an antioxidant, and as a diaphoretic and 
diuretic. It has also appears to have a strong immunological agent, 
stimulating the body's protective mechanisms against disease. The 
Eclectic Botanical physicians considered it to be a potent alterative. 
This property of melittin, being an antioxidant, can be used to 
overcome the free radical effect [26]. 
uPA Receptors 
In order for primary tumours to metastasise, tumour cells must 
undergo a complex series of steps, including detachment from the 
primary tumour, degradation of basement membranes, cell 
migration through the extracellular matrix (ECM), intravasation into 
the circulation, attachment and extravasation at a distant organ site, 
and cell division and growth of a new tumour colony. For all these 
steps, the urokinase plasminogen activator system (uPAS), along 
with members of the matrix metalloproteases (MMPs), has long 
known to play a key role. The urokinase-type plasminogen activator 
(uPA), when bound to its cellular receptor, uPAR, efficiently converts 
plasminogen into the serine protease plasmin, which then facilitates 
the release of several other proteolytic enzymes including 
gelatinase, fibronectin, fibrin, laminin, and latent forms of 
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collagenase needed to degrade physical barriers to cell movement. 
Binding of uPA to its receptor also triggers other important 
biological effects, including chemotaxis, migration, invasion, 
adhesion and proliferation [27]. 
The serpin family of serine protease inhibitors has generated a lot of 
interest in the past few years. One member in particular, maspin, has 
been under intense scrutiny as of late due to its seemingly growing 
potential in the cancer field as a therapeutic agent for breast and 
prostate cancers. Originally identified in a subtractive hybridization 
screen of breast cancer cells, maspin has since been classified as a 
putative tumour suppressor. It has been reported that maspin plays 
a novel role in the regulation of the urokinase-type plasminogen 
activator (uPA) and receptor (uPAR) protein system as it relates to 
hypoxia thereby illustrating yet another potential therapeutic 
pathway involving Maspin [28]. 
The function of the RSL domain of maspin on cell-ECM adhesion and 
tumor invasion has been explored. It is reported that that 1) the 
maspin RSL domain, but not the C-terminal region, is required, 2) 
the RSL peptide is sufficient for induction of increased cell-ECM 
adhesion of corneal stromal cells and carcinoma cells and inhibition 
of carcinoma cell invasion, and 3) the RSL can compete for specific 
binding of maspin to carcinoma cells [29]. 
Melittin (C131H229N39O31
Comparison of the amino acid sequence of maspin with that of bee 
venom shows maximum similarity with melittin. Melittin will show 
anti-cancer effect against breast cancer and cell apoptosis will take 
place. This can happen because the amino acid sequence of the 
reactive site loop of maspin, which is a serine protease inhibitor, 
partially matches with melittin. It can associate either directly with 
the uPA/uPAR complex or indirectly through an integrin or other 
molecule and function as a tumour suppressor.  
) is the main toxin in Apis mellifera 
(honeybee venom), and is characterized as a cationic, water-soluble 
peptide (+6 charge). The active peptide is originally released in the 
hive from its precursor, promelittin, until it is formylated. This 
biosynthesized melittin is comprised of a twenty-six amino acid 
sequence, with a hydrophobic amino-terminal and a hydrophilic 
carboxy-terminal. Melittin gains its biological significance in its 
antimicrobial, lytic abilities [30]. 
Snake Venom 
It has been demonstrated that the snake venom extracted from 
Walterinnesia aegyptia (WEV) either alone or combined with silica 
nanoparticles enhanced the proliferation of mice immune cells and 
simultaneously decreased the proliferation of human breast 
carcinoma cell line (MDA-MB-231) [31]. 
Results have also demonstrated that CTX III inhibition of MDA-MB-
231 cells may occur through inactivation of both PI3K/Akt and p38 
MAPK signalling pathways, exerting inhibitory effects on NF-κB 
transcriptional factor, thereby decreasing the activity of MMP-9 and 
then posing an anti-metastatic effect in the cells [32]. 
Disintegrins 
Disintegrins are low molecular weight peptides isolated from 
viper venom. Rubistatin is a MVD disintegrin cloned from a Crotalus 
ruber venom gland. Recombinant rubistatin (r-Rub) was cloned into 
a pET32b plasmid and expressed in reductase-deficient Escherichia 
coli. Its effect was tested on three cancerous cell lines and was found 
have an anti-proliferative, anti-migratory effect on the same and 
helping in the apoptosis of the same [33]. 
A component of snake venom has demonstrated its ability to inhibit 
cancer cell migration in two different cancer models. The protein, 
called contortrostatin, seems to block cell migration in a novel way. 
A minor component of the venom that worked as a disintegrin, and 
this protein was named contortrostatin. The integrins are a family of 
transmembrane receptor proteins that bind to components of the 
extracellular matrix. One of their functions is to grip the 
extracellular matrix, providing traction and allowing cells to migrate 
from one place to another. Researchers in a number of laboratories 
are focusing on one integrin in particular, called αvβ3. This integrin 
is present on the surface of cancer cells and is thought to be critical 
in metastasis. 
Contortrostatin appears to block cell migration both by binding to a 
cell-surface protein in the integrin family, preventing it from 
gripping the extracellular matrix, and by scrambling signals to the 
cytoskeleton [34]. 
A therapeutic potential of disintegrin present in cobra snake venom 
contains a number of components with different pharmacological 
and biological activities were investigated. A study was designed to 
evaluate the effect of crude snake venom on a level of RNA and DNA 
of normal and breast cancer tissues in vitro. It was observed that in 
comparison to normal tissue the amount of RNA in cancerous tissue 
was higher about 84 %. And when a cancerous tissue was treated 
with snake venom (25 μg/ml) the content was reduced by 25 %. 
Similarly when same procedure was repeated for DNA contents the 
results showed similar pattern and amount of DNA increased in 
cancerous tissues by 57 %. The DNA amount is reduced with snake 
venom (25 μg/ml) by 95 %. Antitumour activity of contortrostatin 
(CN) is based on the high affinity interaction with several integrin 
displayed on both cancer cells and newly growing vascular 
endothelial cells. I. V administration of CN and long chain neurotoxin 
(LCN) effectively inhibits angiogenesis when compared with control. 
The diverse mechanisms of action provide CN with a distinct 
advantage over many other antitumour agents that only block a 
single pathway [35]. 
Cancer cell inhibitors 
Cancer cell inhibitors, named atroporin and kaotree, having 
molecular weights of 35 KDa and 6 KDa have been isolated from the 
venoms of crotalus atrox and naja kaouthia, respectively, by 
fractionation on high pressure liquid chromatography. The purified 
atroporin and kaotree showed killing effects on various types of 
human (breast, colon, liver, ovary, etc.) And animal cancer cells in 
concentrations as low as 0.5µg/ml, and having no effect on normal 
mouse kidney, liver, spleen, and erythrocytes up to 5.0µg/ml. Both 
atroporin and kaotree prevent the formation of ascitic tumors 
caused by myeloma cells in balb/c mice. In addition, both atroporin 
and kaotree showed regression of ascitic tumors formed by 
myeloma cells. Atroporin and kaotree complement each other, as in 
combination they showed elevated anti-cancer activity in 
vitro and in vivo systems. However, atroporin and kaotree are 
immunologically distinct proteins showing no cross reactivity. 
Atroporin and kaotree, individually or in combination, have the 
potential for cancer biotherapy [36]. 
Indian monocellate cobra (Naja kaouthia) and Russell’s viper 
(Vipera russelli) are common snakes of the East Indian sub-
peninsula. The anticarcinogenic activities of their crude venoms 
were studied on carcinoma, sarcoma and leukemia models. Sub-
lethal doses of venoms showed cytotoxicity on Ehrlich ascites 
carcinoma (EAC) cells in vivo. The venoms increased lifespan of EAC 
mice and strengthened the impaired host antioxidant system. 
Sarcoma formation in mice (3-methylcholanthrene induced) after 
venom treatment was significantly less (p<0.005). Histopathological 
examination of tumors showed tissue necrosis. The venoms 
displayed potent cytotoxic and apoptogenic effect on human 
leukemic cells (U937/K562). The venoms reduced cell proliferation 
rate (p < 0.005) and produced morphological alterations indicative 
of apoptosis induction. Different degree and nature of 
anticarcinogenic property of cobra and viper venoms may be 
attributed to the difference in their constituents [37]. 
Potential targets of snake venom 
Anoikis 
Echis carinatus (saw-scaled viper) produces potent hemorrhagic 
venom that causes the development of apoptotic and necrotic 
tissues. In one study, polyethyleneimine (PEI) was used to enhance 
cellular adherence, and to determine whether the substrate 
attachment influenced the survival of cells treated with crude e. 
Carinatus venom. Human embryonic kidney (HEK) 293t cells were 
grown for 18hr in tissue culture plates with or without PEI, and 
were then stimulated with crude E. carinatus venom for 3 or 12hr. 
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HEK 293t cells grown without PEI displayed a robust oxidative 
response to corresponding substrate detachment, loss of plasma 
membrane integrity and decreased cell viability. Cells grown on PEI 
adsorbed substrates demonstrated prolonged substrate attachment 
resulting in significantly higher cell viabilities. These observations 
suggest that the cytotoxicity of crude E. carinatus venom is 
dependent upon cellular detachment. Metallproteases, PLA2, and 
disintegrins from E. carinatus venom promoted apoptosis as a part 
of their pathological mechanisms. For example, in vitro studies using 
adherent cell cultures have shown exposure to purified disintegrins 
or snake venom metalloproteases (SVMP) induce cellular 
detachment. Interestingly, removal of the stimulants enables cellular 
reattachment and cellular survival, suggesting that disintegrins and 
SVMP induces a substrate dependent form of cell death, termed 
anoikis. Anoikis is important for maintaining tissue homeostasis and 
plays an essential role in the prevention of dissemination of cells to 
inappropriate sites, most notably during the metastatic process [38]. 
Anti-inflammatory and anti-neoplasmic activities of PLA2 
Naturally occurring anti-toxic factors that neutralize PLA2 from the 
blood of both venomous and non-venomous animals have been 
isolated and studied. Snake PLA2 inhibitors (PLIS) are large 
multimeric, serum proteins that form soluble complexes with PLA2 
enzymes, thereby inhibiting their actions. PLA2 isolated from 
Bothrops neweidii venom and Indian cobra, Naja naja venom, was 
found to be cytotoxic towards B16 F10 melanoma and ehrlich 
ascites tumour cells, respectively, suggesting its employment as an 
anticancer drug [39]. 
Platelet aggregation inhibitors 
Many snake venom toxins affect platelet function. They can be 
grouped into a few major families, such as enzymes like serine 
proteinases, zinc-dependent pi-piv metalloproteinases of the 
reprolysin family and group II PLA2 isoenzymes as well as proteins 
with no enzymatic activity, such as c-type lectins, crisp and 
disintegrins. Of these, disintegrins and c-type lectins are considered 
as useful modulators of platelet function [39]. 
Indian monocellate cobra (Naja kaouthia) and Russell’s viper 
(Vipera russelli) are common snakes of the East Indian sub-
peninsula. The anticarcinogenic activities of their crude venoms 
were studied on carcinoma, sarcoma and leukemia models. Sub-
lethal doses of venoms showed cytotoxicity on ehrlich ascites 
carcinoma (EAC) cells in vivo. The venoms increased lifespan of EAC 
mice and strengthened the impaired host antioxidant system. 
Sarcoma formation in mice (3 methylcholanthrene induced) after 
venom treatment was significantly less (p < 0.005). 
Histopathological examination of tumors showed tissue necrosis. 
The venoms displayed potent cytotoxic and apoptogenic effect on 
human leukemic cells (U937/K562). The venoms reduced cell 
proliferation rate (p < 0.005) and produced morphological 
alterations indicative of apoptosis induction. Different degree and 
nature of anticarcinogenic property of cobra and viper venoms may 
be attributed to the difference in their constituents [39]. 
Cytotoxins 
Cytotoxins from cobra venom are known to manifest cytotoxicity in 
various cell types. It is widely accepted that the plasma membrane is 
a target of cytotoxins, but the mechanism of their action remains 
obscure. Using the confocal spectral imaging technique, it was 
shown for the first time that cytotoxins from cobra venom penetrate 
readily into living cancer cells and accumulate markedly in 
lysosomes. Cytotoxins CT1 and CT2 from Naja oxiana, CT3 from Naja 
kaouthia and CT1 from Naja haje are demonstrated to possess this 
property with respect to human lung adenocarcinoma A549 and 
promyelocytic leukaemia HL60 cells. Immobilized plasma 
membrane binding accompanies the internalization of CT3 from 
Naja kaouthia in the HL60 cells, but it is very weak for other 
cytotoxins. Detectable membrane binding is not a property of any of 
the cytotoxins tested in A549 cells. The kinetics and concentration-
dependence of cytotoxin accumulation in lysosomes correlate well 
with their cytotoxic effects. On the basis of the results obtained, it 
was proposed that lysosomes are a primary target of the lytic action 
of cytotoxins. Plasma membrane permeabilization seems to be a 
downstream event relative to lysosome rupture. Direct damage to 
the plasma membrane may be a complementary mechanism, but its 
relative contribution to the cytotoxic action depends on the 
cytotoxin structure and cell type [40]. 
Scorpion Venom 
Venom of some species of scorpions induces apoptosis and arrests 
proliferation in cancer cells. This is an important property that can 
be harnessed and can lead to isolation of compounds of therapeutic 
importance in cancer research.  
The venom toxins isolated from Indian black scorpion, Heterometrus 
bengalensis show cytotoxic activity to leukemic cells and induced cell 
cycle arrest at G1 phase. Similarly, charybdotoxins isolated from the 
venom of Leiurus quinquestraius herbraeus arrest the cancerous cells 
in early G1 late G1 and S phase of cell cycle. A short peptide BMK-
CBP isolated from Chinese scorpion Buthus martensii Karsch binds 
to cancer cell lines MCF-1 and inhibits cell growth. Similarly, 
BmYYAI, APBMV and BmKITal peptides isolated from red scorpion 
show anticancer activity by enhancing the activation and 
proliferation of lymphocytes and induction of immune function of 
WBCs in mice. Morespecially, Buthus martensii Karsch venom 
contains cholorotoxins which induce cell death in malignant glioma 
cells. These are used as novel tool for detection of skin cervical lung 
cancer, breast, prostate and testicular cancers and tumors. Similar 
activity is also showed by serine proteinase and hyaluronidase 
present in scorpion venom. Cercopins isolated from insects show 
anticancer activity [41]. 
Two novel peptides named neopladine 1 and neopladine 2 were 
purified from Tityus discrepans scorpion venom and found to be 
active on human breast carcinoma SKBR3 cells. Mass spectrometry 
molecular masses of neopladine 1 and 2 were 29918 and 30388 Da, 
respectively. Their N-terminal sequences were determined by 
Edman degradation. The peptides induced apoptosis of SKBR3 cells 
but had a negligible effect on non-malignant MA104 monkey kidney 
cells. Neopladine 1 and 2 induced 6.3 and 4.1% of SKBR3 apoptosis, 
respectively, in 5 h of exposure; the effect was larger with more 
prolonged exposures. Immunohistochemistry showed that 
neopladines bind to SKBR3 cell surface inducing FAS-L and BCL-2 
expression [42]. 
Another study was done to examine the cytotoxic and anti-
cancer properties along with addressing the plausible pathway 
followed by scorpion venom to reduce cell viability in SH-SY5Y and 
MCF-7 cells. Following exposure of cells with scorpion venom, 
cytotoxicity was estimated using MTT and lactate dehydrogenase 
assays. Apoptotic effects were measured by assessment of 
mitochondrial membrane potential, reactive nitrogen species, DNA 
fragmentation, and caspase-3 activity whereas antiproliferative 
effect was assayed using BrdU incorporation. The results indicate 
that scorpion venom causes suppression of proliferation by 
arresting S-phase and induction of apoptosis through increased 
nitric oxide production, caspase-3 activity and depolarization of 
mitochondrial membrane. Induction of apoptosis and arrest of DNA 
synthesis are critical determinant factors for development of anti-
cancer drugs. These properties may lead to isolation of effective 
molecule(s) with potential anticancer activity from scorpion 
venom of Androctonus crassicauda [43]. 
MTT reduction assay has been used to measure cytotoxicity and 
confirmed with lactate dehydrogenase release 
following venom exposure. Inhibition of DNA synthesis in 
proliferating breast cancer cells was confirmed using 
immunocytochemical detection of BrdU incorporation. Results 
demonstrate that venom of Odontobuthus doriae not only induces 
apoptosis but lead to the inhibition of DNA synthesis in 
human breast cancer cells (MCF-7). Cell viability decreased with 
parallel increment of LDH release in dose dependent manner after 
treatment with varying concentrations of venom. These events were 
related to the depolarization of mitochondria and associated 
Caspase-3 activation following venom treatment in a concentration 
dependent manner. Finally, fragmentation of nuclear DNA 
following venom treatment confirmed the apoptotic property of the 
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said venom. These results suggest that venom of O. doriae can be 
potential source for the isolation of effective anti-proliferative and 
apoptotic molecules [43]. 
Spider Venom 
Scorpion venoms are a complex mixture of a large variety of 
molecules and they play an important role in the defence and 
capture of prey. They contain mucopolysaccarides, phospholipases, 
hyaluronidases, protease inhibitors, low molecular weight molecules 
such as serotonin and histamine, histamine releasing peptides, 
inorganic salts, mucus, and many basic small proteins called 
neurotoxic peptides. The latter have specific interaction with ion 
channels, making scorpion venom capable of binding specifically to 
certain types of cells, such as cancer cells; therefore, this type of 
venom holds molecules that are of interest to the pharmaceutical 
industry in terms of drug design and development [44]. 
Spider venoms are a rich source of bioactive compounds with 
therapeutic potential. The venom of the spider Macrothele raveni 
potently suppresses cell growth in the myelogenous leukaemia K562 
cell line in a dose and time-dependent manner with an IC (50) of 5.1 
μg/mL. The results indicate that the venom of the spider M. raveni 
potently and selectively suppresses the growth of K562 cells by 
inducing apoptosis via caspase 3 and caspase 8 mediated signalling 
pathways [45]. 
A study was done to examine the effects of antitumor activity of 
the venom from the spider Macrothele raven (Araneae, 
Hexathelidae) on the human breast carcinoma cell line, MCF-7. 
The spider venom affected cell viability in a dose- and time-
dependent manner as observed by [(3)H]-methyl thymidine 
incorporation assay. Cytotoxicity changes in MCF-7 cells caused by 
the spider venom at concentrations of 10, 20, and 40 mug/mL were 
determined by lactate dehydrogenase release assay. Flow cytometry 
showed that the spider venom induced apoptosis and necrosis of 
MCF-7 cells at these concentrations. MCF-7 cells treated with spider 
venom were accumulated on the G(2)/M and G(0)/G(1) phases. In 
addition, Western blotting analysis indicated that one of the 
pharmacological mechanisms of spider venom was to activate the 
expression of p21. In vivo examination of the inhibition of tumor 
growth in nude mice by the spider venom (at concentrations of 1.6, 
1.8, and 2.0 mug/g mice) revealed that tumor size significantly 
decreases compared to controls by 21 days of treatment and at all 
points of analysis thereafter for 7 weeks (p < 0.01). [16]. 
Toad Venom 
Bombesin 
A study has demonstrated that bombesin/GRP antagonists reduces 
the expression of mRNA and protein levels of the most significant 
proangiogenic factors in breast cancer. These angiogenic and 
growth-promoting substances closely interact with each other. The 
tumor-inhibitory effect of bombesin/GRP antagonists appears to 
involve complex mechanisms. In this regard, it has been reported 
that RC-3095 and RC-3940-II can inhibit the growth of MDA-MB-435 
cancer by downregulating mainly ErbB-2/HER-2, as well as by 
decreasing the expression of c-jun and c-fosoncogenes. Therefore, 
the mechanism responsible for the action of these antagonists on 
angiogenesis could be mediated by a downregulation of ErbB-
2/HER-2, which would affect the pathways described above, and 
finally facilitate a decrease in the expression of the growth factors 
and MMPs as well as the vascular content. These findings confirm 
the merit of continued investigations of bombesin/GRP antagonists 
for the development of another approach to the management of 
breast cancer [46]. 
Brevinin 
Brevinin-2R is a novel non-hemolytic defensin that was isolated 
from the skin of the frog Rana ridibunda. It exhibits preferential 
cytotoxicity towards malignant cells, including Jurkat (T-cell 
leukemia), BJAB (B-cell lymphoma), HT29/219, SW742 (colon 
carcinomas), L929 (fibrosarcoma), MCF-7 (breast adenocarcinoma), 
A549 (lung carcinoma), as compared to primary cells including 
peripheral blood mononuclear cells (PBMC), T cells and human lung 
fibroblasts. Jurkat and MCF-7 cells overexpressing Bcl2, and L929 
and MCF-7 overexpressing a dominant-negative mutant of a pro-
apoptotic BNIP3 were largely resistant towards Brevinin-2R 
treatment. The decrease in mitochondrial membrane potential, or 
total cellular ATP levels, and increased reactive oxygen species 
(ROS) production, but not caspase activation or the release of 
apoptosis-inducing factor (AIF) or endonuclease G (Endo G), are 
early indicators of Brevinin-2R triggered death. Brevinin-2R 
interacts with both early and late endosomes. Lysosomal membrane 
permeabilization inhibitors and inhibitors of cathepsin-B and 
cathepsin-L prevented Brevinin-2R-induced cell death. 
Autophagosomes have been detected upon Brevinin-2R treatment. 
Results have shown that Brevinin-2R activates the lysosomal-
mitochondrial death pathway, and involves autophagy-like cell 
death [47]. 
Bufalin 
Bufalin is the major digoxin-like immunoreactive component of 
Chan Su, a traditional Chinese medicine obtained from the skin and 
parotid venom glands of the toad. Bufalin and other bufadienolides 
are cardioactive C-24 steroids that exhibit a variety of biological 
activities, such as cardiotonic, anesthetic, blood pressure 
stimulation, respiration and antineoplastic activities. In terms of its 
anti-tumor activities, bufalin has demonstrated to induce growth 
inhibition, cell cycle arrest and apoptosis of tumor cells. Bufalin can 
be safely used for long periods without severe side effects. At high 
dosages, however, cardioactive steroids cause cardiac arrhythmia, 
breathlessness, seizure and coma. The structural similarity between 
bufadienolides and digoxin accounts for the toxic effects. Bufalin 
greatly sensitized ER-alpha-positive MCF-7 and ER-alpha-negative 
MDA-MB-231 human breast cancer cells to TRAIL-induced 
apoptosis. Enhanced apoptotic effects by TRAIL/bufalin combo were 
associated with augmentation of caspases activation. Further 
mechanistic investigation demonstrated that bufalin was able to 
significantly decrease Mcl-1 and BclXL expression levels, and inhibit 
the transcription factor STAT3. The important consequence of 
downregulation Mcl-1 in the enhancement action by combining 
bufalin with TRAIL was confirmed by either knockdown or 
overexpression of Mcl-1 approach [48]. 
Bufadienolides 
The term “Bufodienolides” derives from the toad genus Bufo that 
contains bufadienolide glycosides, the suffix -adien- that refers to 
the two double bonds in the lactone ring, and the ending -olide that 
denotes the lactone structure. Bufadienolides are C-24 steroids; its 
characteristic structural feature is a doubly unsaturated six 
membered lactone ring having a 2-pyrone group attached at the C-
17β position of the perhydrophenanthrene nucleus. On account of 
this chromophoric ring, they possess a characteristic UV absorption. 
Bufadienolides are a new type of natural steroids with potent 
antitumor activities. They have been reported to exhibit significant 
inhibitory activities against human myeloid leukemia cells (K562, 
U937, ML1, HL60), human hepatoma cells (SMMC7221), and 
prostate cancer cells (LNCaP, DU105, PC3). The activities are 
mediated by induction of cell apoptosis and cell differentiation, and 
the regulations of a variety of genes and proteins are involved in the 
process [49]. 
The death receptor ligand TRAIL is considered a promising 
candidate for cancer therapy because of its preferential toxicity to 
malignant cells. However its efficacy has been challenged by a 
number of resistance mechanisms. Therefore, agents that can 
overcome the resistance to enhance therapeutic efficacy of TRAIL 
are needed. In one study it was found that bufalin, bufotalin and 
gamabufotalin, key members of bufadienolides isolated from a 
traditional Chinese medicine ChanSu, significantly potentiated 
human breast cancer cells with different status of ER-alpha to 
apoptosis induction of TRAIL, as evidenced by enhanced Annexin 
V/FITC positive cells (apoptotic cells), cytoplasmic histone-
associated-DNA-fragments, membrane permeability transition 
(MPT), caspases activation and PARP cleavage. Further mechanistic 
investigation demonstrated that bufalin was able to significantly 
decrease Mcl-1 expression and modestly decrease Bcl-XL expression 
level. Down-regulations of these anti-apoptotic proteins were well 
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correlated with inhibition of transcription factor STAT3 activation. 
The important consequence of down-regulation Mcl-1 in the 
enhancement action by combining bufalin with TRAIL was 
confirmed by either knockdown or overexpression of Mcl-1 
approach. These findings for the first time provided strong 
evidences that bufadienolide compounds have excellent potential to 
be developed as a novel class of sensitizers of TRAIL [50]. 
CONCLUSION 
Venom contains some broad spectrum of ion channel toxins that 
dominate medical importance. As with most species, there is 
evidence for novel activities in the presence of a high molecular 
weight, pulmonary edema inducing toxin is particularly intriguing. 
Some toxins appear to block cell migration by binding to a cell-
surface protein in the integrin family, preventing it from gripping 
the extracellular matrix, and by scrambling signals to the 
cytoskeleton. It will be a long road for the venom from laboratory to 
clinic. To have results on cell-line or model organisms is completely 
different from pre-clinical or clinical trials and has to be conform with 
the pharmacological properties, which evidently are major stumbling 
blocks going from an interesting cell-biological observations to a 
market offering. The other major hurdle can also be the ethics or wild 
life regarding the use of venom. Nevertheless, the question remains, 
can this be developed as an anti-breast cancer drug? 
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